secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2021-09-28T23:59:59+00:00
Accession:  0001437749-21-022771
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex appoints Dr. Berger as CMO and Dr. Kumar as CMTO, effective Sept 27, 2021
--------------------------------------------------------------------------------

- Mark S. Berger, M.D. named Chief Medical Officer; annual base salary $450,000 plus up to 40% bonus and 550k stock option at $2.85/sh.
- Hemant Kumar, Ph.D. named Chief Manufacturing and Technology Officer; base salary $325,000 plus up to 40% bonus and 400k stock option at $2.85/sh.
- Both roles are newly created; Berger and Kumar report to CEO Rodney Varner.
- Berger previously CMO at Actinium Pharmaceuticals; Kumar most recently VP at Arcturus Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774921022771/0001437749-21-022771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774921022771/gnpx20210928_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-022771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer